PCSK9 Inhibitors (e.g., Evolocumab)
Treatment for Coronary Artery Disease
Typical Dosage: Evolocumab: 140mg every 2 weeks or 420mg monthly (subcutaneous)
Effectiveness
78%
Safety Score
65%
Clinical Trials
50
Participants
70K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Evolocumab: 140mg every 2 weeks or 420mg monthly (subcutaneous)
Time to Effect
2-4 weeks for LDL-C reduction, 6-12 months for cardiovascular event reduction
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
70(Treat 70 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,000
Monitoring:$100
Side Effect Mgmt:$20
Total Annual:$5,120
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$34,133
Comparison vs Standard Statin Therapy
Cost Difference
+$4,880/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
PCSK9 Inhibitors (e.g., Evolocumab) Outcomes
for Coronary Artery Disease
Efficacy Outcomes
Overall Effectiveness
+78%
Response Rate
+15%
Common Side Effects
Injection site reactions
+5%
Nasopharyngitis
+10%
Flu-like symptoms
+3%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov